tetano
Editor, Senior Moderator
J Med Case Rep
. 2025 Mar 27;19(1):143.
doi: 10.1186/s13256-025-05188-0. Seven-month persistence of COVID-19 vaccine-induced lymphadenopathy: a case report
Matthew K Hwang[SUP] 1 [/SUP], Hemi Dua[SUP] 2 3 [/SUP], Anna Marie Mulligan[SUP] 4 5 [/SUP], Jaime Escallon[SUP] 6 [/SUP]
Affiliations
Background: Lymphadenopathy is a known side effect of both messenger RNA and viral vector coronavirus disease-2019 vaccines and can cause a spectrum of findings. Coronavirus disease-2019 vaccine-associated lymphadenopathy typically resolves within 60 days after administration of the dose.
Case presentation: A 59 year old Chinese woman underwent routine mammographic screening that revealed scattered areas of fibroglandular densities in the lower-inner quadrant of the left breast and abnormal lymph nodes. A core biopsy of the breast identified ductal carcinoma in situ. A biopsy of the lymph nodes was performed, and histological findings and immunophenotype were consistent with lymphoid hyperplasia. This patient had sought medical attention after she detected swelling in her left supraclavicular fossa 7 months earlier. She had received the first dose of the Pfizer coronavirus disease-2019 vaccine in the left deltoid muscle 7 days prior to presenting with left supraclavicular fossa swelling.
Conclusion: After reviewing the history, imaging, and pathology, it was concluded through a diagnosis of exclusion that the observed enlarged left axillary lymph nodes with reactive histology were probably related to the coronavirus disease-2019 vaccine administration and not to ductal carcinoma in situ or an undetected invasive cancer. Clinicians and radiologists need to be aware of the potential for abnormal presentations of persistent lymphadenopathy that may interfere with the diagnosis and follow-up of cancers.
Keywords: COVID-19; Lymphadenopathy; Vaccine.
. 2025 Mar 27;19(1):143.
doi: 10.1186/s13256-025-05188-0. Seven-month persistence of COVID-19 vaccine-induced lymphadenopathy: a case report
Matthew K Hwang[SUP] 1 [/SUP], Hemi Dua[SUP] 2 3 [/SUP], Anna Marie Mulligan[SUP] 4 5 [/SUP], Jaime Escallon[SUP] 6 [/SUP]
Affiliations
- PMID: 40148999
- PMCID: PMC11951827
- DOI: 10.1186/s13256-025-05188-0
Background: Lymphadenopathy is a known side effect of both messenger RNA and viral vector coronavirus disease-2019 vaccines and can cause a spectrum of findings. Coronavirus disease-2019 vaccine-associated lymphadenopathy typically resolves within 60 days after administration of the dose.
Case presentation: A 59 year old Chinese woman underwent routine mammographic screening that revealed scattered areas of fibroglandular densities in the lower-inner quadrant of the left breast and abnormal lymph nodes. A core biopsy of the breast identified ductal carcinoma in situ. A biopsy of the lymph nodes was performed, and histological findings and immunophenotype were consistent with lymphoid hyperplasia. This patient had sought medical attention after she detected swelling in her left supraclavicular fossa 7 months earlier. She had received the first dose of the Pfizer coronavirus disease-2019 vaccine in the left deltoid muscle 7 days prior to presenting with left supraclavicular fossa swelling.
Conclusion: After reviewing the history, imaging, and pathology, it was concluded through a diagnosis of exclusion that the observed enlarged left axillary lymph nodes with reactive histology were probably related to the coronavirus disease-2019 vaccine administration and not to ductal carcinoma in situ or an undetected invasive cancer. Clinicians and radiologists need to be aware of the potential for abnormal presentations of persistent lymphadenopathy that may interfere with the diagnosis and follow-up of cancers.
Keywords: COVID-19; Lymphadenopathy; Vaccine.